The Application of Nanobody in CAR-T Therapy
Chimeric antigen receptor (CAR) T therapy represents a form of immune cellular therapy with clinical efficacy and a specific target. A typical chimeric antigen receptor (CAR) construct consists of an antigen binding domain, a transmembrane domain, and a cytoplasmic domain. Nanobodies have been widel...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-02-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/11/2/238 |
| _version_ | 1797412793625870336 |
|---|---|
| author | Chaolemeng Bao Quanli Gao Lin-Lin Li Lu Han Bingxiang Zhang Yijin Ding Zongpei Song Ruining Zhang Jishuai Zhang Xian-Hui Wu |
| author_facet | Chaolemeng Bao Quanli Gao Lin-Lin Li Lu Han Bingxiang Zhang Yijin Ding Zongpei Song Ruining Zhang Jishuai Zhang Xian-Hui Wu |
| author_sort | Chaolemeng Bao |
| collection | DOAJ |
| description | Chimeric antigen receptor (CAR) T therapy represents a form of immune cellular therapy with clinical efficacy and a specific target. A typical chimeric antigen receptor (CAR) construct consists of an antigen binding domain, a transmembrane domain, and a cytoplasmic domain. Nanobodies have been widely applied as the antigen binding domain of CAR-T due to their small size, optimal stability, high affinity, and manufacturing feasibility. The nanobody-based CAR structure has shown a proven function in more than ten different tumor-specific targets. After being transduced in Jurkat cells, natural killer cells, or primary T cells, the resulting nanobody-based CAR-T or CAR-NK cells demonstrate anti-tumor effects both in vitro and in vivo. Interestingly, anti-BCMA CAR-T modulated by a single nanobody or bi-valent nanobody displays comparable clinical effects with that of single-chain variable fragment (scFv)-modulated CAR-T. The application of nanobodies in CAR-T therapy has been well demonstrated from bench to bedside and displays great potential in forming advanced CAR-T for more challenging tasks. |
| first_indexed | 2024-03-09T05:08:25Z |
| format | Article |
| id | doaj.art-c302d49a0d7d4ae08ba98e3425062ffd |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-09T05:08:25Z |
| publishDate | 2021-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-c302d49a0d7d4ae08ba98e3425062ffd2023-12-03T12:52:33ZengMDPI AGBiomolecules2218-273X2021-02-0111223810.3390/biom11020238The Application of Nanobody in CAR-T TherapyChaolemeng Bao0Quanli Gao1Lin-Lin Li2Lu Han3Bingxiang Zhang4Yijin Ding5Zongpei Song6Ruining Zhang7Jishuai Zhang8Xian-Hui Wu9Shenzhen Pregene Biopharma Company Ltd., Shenzhen 518118, ChinaDepartment of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou 450008, ChinaDepartment of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou 450008, ChinaDepartment of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou 450008, ChinaShenzhen Pregene Biopharma Company Ltd., Shenzhen 518118, ChinaShenzhen Pregene Biopharma Company Ltd., Shenzhen 518118, ChinaShenzhen Pregene Biopharma Company Ltd., Shenzhen 518118, ChinaShenzhen Pregene Biopharma Company Ltd., Shenzhen 518118, ChinaShenzhen Pregene Biopharma Company Ltd., Shenzhen 518118, ChinaShenzhen Pregene Biopharma Company Ltd., Shenzhen 518118, ChinaChimeric antigen receptor (CAR) T therapy represents a form of immune cellular therapy with clinical efficacy and a specific target. A typical chimeric antigen receptor (CAR) construct consists of an antigen binding domain, a transmembrane domain, and a cytoplasmic domain. Nanobodies have been widely applied as the antigen binding domain of CAR-T due to their small size, optimal stability, high affinity, and manufacturing feasibility. The nanobody-based CAR structure has shown a proven function in more than ten different tumor-specific targets. After being transduced in Jurkat cells, natural killer cells, or primary T cells, the resulting nanobody-based CAR-T or CAR-NK cells demonstrate anti-tumor effects both in vitro and in vivo. Interestingly, anti-BCMA CAR-T modulated by a single nanobody or bi-valent nanobody displays comparable clinical effects with that of single-chain variable fragment (scFv)-modulated CAR-T. The application of nanobodies in CAR-T therapy has been well demonstrated from bench to bedside and displays great potential in forming advanced CAR-T for more challenging tasks.https://www.mdpi.com/2218-273X/11/2/238nanobodyV<sub>H</sub>HCAR-TBCMA |
| spellingShingle | Chaolemeng Bao Quanli Gao Lin-Lin Li Lu Han Bingxiang Zhang Yijin Ding Zongpei Song Ruining Zhang Jishuai Zhang Xian-Hui Wu The Application of Nanobody in CAR-T Therapy Biomolecules nanobody V<sub>H</sub>H CAR-T BCMA |
| title | The Application of Nanobody in CAR-T Therapy |
| title_full | The Application of Nanobody in CAR-T Therapy |
| title_fullStr | The Application of Nanobody in CAR-T Therapy |
| title_full_unstemmed | The Application of Nanobody in CAR-T Therapy |
| title_short | The Application of Nanobody in CAR-T Therapy |
| title_sort | application of nanobody in car t therapy |
| topic | nanobody V<sub>H</sub>H CAR-T BCMA |
| url | https://www.mdpi.com/2218-273X/11/2/238 |
| work_keys_str_mv | AT chaolemengbao theapplicationofnanobodyincarttherapy AT quanligao theapplicationofnanobodyincarttherapy AT linlinli theapplicationofnanobodyincarttherapy AT luhan theapplicationofnanobodyincarttherapy AT bingxiangzhang theapplicationofnanobodyincarttherapy AT yijinding theapplicationofnanobodyincarttherapy AT zongpeisong theapplicationofnanobodyincarttherapy AT ruiningzhang theapplicationofnanobodyincarttherapy AT jishuaizhang theapplicationofnanobodyincarttherapy AT xianhuiwu theapplicationofnanobodyincarttherapy AT chaolemengbao applicationofnanobodyincarttherapy AT quanligao applicationofnanobodyincarttherapy AT linlinli applicationofnanobodyincarttherapy AT luhan applicationofnanobodyincarttherapy AT bingxiangzhang applicationofnanobodyincarttherapy AT yijinding applicationofnanobodyincarttherapy AT zongpeisong applicationofnanobodyincarttherapy AT ruiningzhang applicationofnanobodyincarttherapy AT jishuaizhang applicationofnanobodyincarttherapy AT xianhuiwu applicationofnanobodyincarttherapy |